Literature DB >> 25687162

A head-to-head comparison of homocysteine and cystatin C as pre-procedure predictors for contrast-induced nephropathy in patients undergoing coronary computed tomography angiography.

Suhua Li1, Xixiang Tang2, Long Peng1, Yanting Luo1, Yunyue Zhao1, Lin Chen1, Ruimin Dong1, Jieming Zhu1, Yanming Chen2, Jinlai Liu3.   

Abstract

BACKGROUND: Homocysteine is a potential predictor for contrast-induced nephropathy (CIN). We aimed to compare homocysteine with cystatin C as pre-procedure predictors for CIN in patients undergoing coronary computed tomography angiography (CCTA).
METHODS: A total of 580 consecutive patients were enrolled. Concentrations of plasma homocysteine and serum cystatin C were measured before CCTA. CIN is defined as an elevation of creatinine by ≥ 25% or ≥ 0.5mg/dl from baseline within 48h. Receiver operating characteristic curves, Pearson correlation coefficients and logistic regression analysis were used to evaluate the efficiency of potential predictors.
RESULTS: Fifty-seven (9.83%) patients developed CIN. Concentrations of homocysteine (19.35 ± 4.32 μmol/l vs. 13.42 ± 3.96 μmol/l, p<0.001) and cystatin C (1.20 ± 0.21 mg/dl vs. 0.99 ± 0.15 mg/dl, p<0.001) increased significantly in CIN subjects. CIN was predicted by homocysteine (AUC 0.829, p<0.001) and cystatin C (AUC 0.774, p<0.001), while creatinine was not predictive. Both homocysteine and cystatin C had positive correlation with ΔCreatinine48h-0 (p<0.001) and negative correlation with ΔeGFR48h-0 (p<0.001). Regression analysis confirmed that increased baseline homocysteine [OR: 1.262 (1.123, 2.554), p<0.001] and cystatin C [OR: 1.565 (1.380, 1.775), p<0.001] were independent predictors for CIN.
CONCLUSIONS: Homocysteine, with similar predictive value compared to cystatin C, was an independent biomarker for predicting CIN before CCTA examination.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Computed tomography angiography; Contrast-induced nephropathy; Creatinine; Cystatin C; Homocysteine

Mesh:

Substances:

Year:  2015        PMID: 25687162     DOI: 10.1016/j.cca.2015.02.019

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Reducing both radiation and contrast doses in coronary CT angiography in lean patients on a 16-cm wide-detector CT using 70 kVp and ASiR-V algorithm, in comparison with the conventional 100-kVp protocol.

Authors:  Yuhuan Chen; Zhentang Liu; Michelle Li; Yong Yu; Yongjun Jia; Guangming Ma; Zhijun Hu; DongHong Wei; Dou Li; Taiping He
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

2.  Incidence of persistent renal dysfunction after contrast enhanced coronary CT angiography in patients with suspected coronary artery disease.

Authors:  Teemu Maaniitty; Iida Stenström; Valtteri Uusitalo; Heikki Ukkonen; Sami Kajander; Jeroen J Bax; Antti Saraste; Juhani Knuuti
Journal:  Int J Cardiovasc Imaging       Date:  2016-07-12       Impact factor: 2.357

3.  High mobility group box 1 and homocysteine as preprocedural predictors for contrast-induced acute kidney injury after percutaneous coronary artery intervention.

Authors:  Changhua Mo; Xiao Ma; Wen Jian; Qili Huang; Wenbo Zheng; Zhijie Yang; Yutao Xu; Chun Gui
Journal:  Int Urol Nephrol       Date:  2021-11-02       Impact factor: 2.370

4.  Predictive value of cystatin C and neutrophil gelatinase-associated lipocalin in contrast-induced nephropathy: A meta-analysis.

Authors:  Yi He; Yunzhen Deng; Kaiting Zhuang; Siyao Li; Jing Xi; Junxiang Chen
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

5.  Malnutrition and the risk for contrast-induced acute kidney injury in patients with coronary artery disease.

Authors:  Liling Chen; Zhidong Huang; Weiguo Li; Yibo He; Jingjing Liang; Jin Lu; Yanfang Yang; Haozhang Huang; Yihang Lin; Rongwen Lin; Mengfei Lin; Yan Liang; Yunzhao Hu; Jianfeng Ye; Yuying Hu; Jin Liu; Yong Liu; Yong Fang; Kaihong Chen; Shiqun Chen
Journal:  Int Urol Nephrol       Date:  2021-06-25       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.